BBB-targeting, protein-based nanomedicines for drug and nucleic acid delivery to the CNS
Posted by Ernesto on Tuesday, 3 June 2025
Autores:
Hugo Peluffo 1 , Ugutz Unzueta 2 , María Luciana Negro-Demontel 1 , Zhikun Xu 2 , Esther Váquez 2 , Neus Ferrer-Miralles 2 , Antonio Villaverde 2
Revista (o libro):
Biotechnol Adv
Año:
2015
Mes-dia:
0300
issue, vol, paginas, etc:
33(2):277-87
doi:
10.1016/j.biotechadv.2015.02.004
PMID:
25698504
Abstract:
The increasing incidence of diseases affecting the central nervous system (CNS) demands the urgent development of efficient drugs. While many of these medicines are already available, the Blood Brain Barrier and to a lesser extent, the Blood Spinal Cord Barrier pose physical and biological limitations to their diffusion to reach target tissues. Therefore, efforts are needed not only to address drug development but specially to design suitable vehicles for delivery into the CNS through systemic administration. In the context of the functional and structural versatility of proteins, recent advances in their biological fabrication and a better comprehension of the physiology of the CNS offer a plethora of opportunities for the construction and tailoring of plain nanoconjugates and of more complex nanosized vehicles able to cross these barriers. We revise here how the engineering of functional proteins offers drug delivery tools for specific CNS diseases and more transversally, how proteins can be engineered into smart nanoparticles or 'artificial viruses' to afford therapeutic requirements through alternative administration routes.
Afiliaciones:
1 Neuroinflammation Gene Therapy Laboratory, Institut Pasteur de Montevideo, Montevideo, Uruguay; Departamento de Histología y Embriología, Facultad de Medicina, Universidad de la República (UDELAR), Montevideo, Uruguay.
2 Institut de Biotecnologia i de Biomedicina, Universitat Autònoma de Barcelona, Bellaterra, 08193 Barcelona, Spain; Department de Genètica i de Microbiologia, Universitat Autònoma de Barcelona, Bellaterra, 08193 Barcelona, Spain; CIBER en Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Bellaterra, 08193 Barcelona, Spain.
Enlace pubmed:
https://pubmed.ncbi.nlm.nih.gov/25698504/
Enlace full text:
https://linkinghub.elsevier.com/retrieve/pii/S0734-9750(15)00029-4
Cita:
Peluffo H, Unzueta U, Negro-Demontel ML, Xu Z, Váquez E, Ferrer-Miralles N, Villaverde A. BBB-targeting, protein-based nanomedicines for drug and nucleic acid delivery to the CNS. Biotechnol Adv. 2015 Mar-Apr;33(2):277-87. doi: 10.1016/j.biotechadv.2015.02.004. Epub 2015 Feb 16. PMID: 25698504.